{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:14:46Z","timestamp":1791357286052,"version":"4.3.1"},"reference-count":27,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,4,28]],"date-time":"2014-04-28T00:00:00Z","timestamp":1398643200000},"content-version":"vor","delay-in-days":1182,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2011,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Carbamazepine (CBZ), a frequently used anticonvulsant drug, is one of the most common causes of life\u2010threatening cutaneous adverse drug reactions such as toxic epidermal necrolysis (TEN) and Stevens\u2013Johnson syndrome (SJS). Recent studies have revealed a strong association between HLA\u2010B*1502 and CBZ\u2010induced TEN\/SJS in the Taiwan Han Chinese population.<\/jats:p><jats:p><jats:bold>Objectives\u2002<\/jats:bold> This study is aimed to investigate the association between human leucocyte antigens (HLA) and CBZ\u2010induced TEN\/SJS in the multi\u2010ethnic Malaysian population.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> A sample of 21 unrelated patients with CBZ\u2010induced TEN\/SJS and 300 race\u2010matched, healthy controls were genotyped for HLA\u2010A, \u2010B and \u2010DR using polymerase chain reaction (PCR). Allele frequencies were compared.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> HLA\u2010B*1502 was present in 75.0% (12\/16) of Malay patients with CBZ\u2010induced TEN\/SJS but in only 15.7% (47\/300) of normal controls (odds ratio 16.15, 95% confidence interval 4.57\u201362.4; corrected <jats:italic>P<\/jats:italic>\u2010value\u2003=\u20037.87\u2003\u00d7\u200310<jats:sup>\u22126<\/jats:sup>), which suggests a strong association between HLA and CBZ\u2010induced TEN\/SJS. Additionally, HLA\u2010B*1502 was found in all three Chinese and two Indian patients. Existing data show that frequencies of the HLA\u2010B*1502 allele are generally much higher in Asian populations than in White European populations, which explains the higher incidences of SJS and TEN in Asian countries.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> HLA\u2010B*1502 is strongly associated with CBZ\u2010induced TEN\/SJS in the Malay population in Malaysia, as has been seen in Han Chinese in Taiwan. This indicates that the genetic association apparent in the incidence of CBZ\u2010induced TEN\/SJS is linked with the presence of HLA\u2010B*1502, irrespective of racial origin. Screening of patients for this genetic marker can help to prevent the occurrence of TEN\/SJS.<\/jats:p>","DOI":"10.1111\/j.1365-4632.2010.04745.x","type":"journal-article","created":{"date-parts":[[2011,1,19]],"date-time":"2011-01-19T11:53:20Z","timestamp":1295438000000},"page":"221-224","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":173,"title":["Association of HLA\u2010B*1502 allele with carbamazepine\u2010induced toxic epidermal necrolysis and Stevens\u2013Johnson syndrome in the multi\u2010ethnic Malaysian population"],"prefix":"10.1111","volume":"50","author":[{"given":"Choong\u2010Chor","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun\u2010Lai","family":"Too","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahnaz","family":"Murad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suraiya Hani","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,4,28]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1987.03390150084040"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00096.x"},{"key":"e_1_2_7_4_2","volume-title":"Annual Report 2007","author":"Malaysian Adverse Drug Reactions Advisory Committee","year":"2007"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1986.03380240052027"},{"key":"e_1_2_7_6_2","first-page":"765","article-title":"Rates of cutaneous reactions to drugs","volume":"137","author":"Bigby M","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_7_7_2","first-page":"165","article-title":"Cutaneous adverse drug reactions in a hospital setting","volume":"108","author":"Rademaker M","year":"1995","journal-title":"N Z Med J"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/428486a"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.fpc.0000199500.46842.4a"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01022.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.tpj.6500356"},{"key":"e_1_2_7_12_2","volume-title":"General Report of the Population and Housing Census 2000","year":"2005"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12388434"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.310.6973.170"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-1809.1955.tb01348.x"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-1809.1955.tb01285.x"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00130832-200208000-00003"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.06.017"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0198-8859(01)00247-6"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0039.2002.590308.x"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.2007.00982.x"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.2007.00932.x"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.2005.00474.x"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0039.2000.560606.x"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.2005.00386.x"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0198-8859(00)00186-5"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1159\/000019057"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0198-8859(01)00290-7"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-4632.2010.04745.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-4632.2010.04745.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T23:59:16Z","timestamp":1697327956000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-4632.2010.04745.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["10.1111\/j.1365-4632.2010.04745.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-4632.2010.04745.x","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2]]},"assertion":[{"value":"2014-04-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}